Posted by Michael Wonder on 04 Aug 2023
Setmelanotide acetate for the treatment of people with obesity and hyperphagia associated with Bardet-Biedl syndrome
3 August 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use of setmelanotide acetate in the NHS in England.
Setmelanotide acetate is not recommended for the treatment of people aged 6 years and over with obesity and hyperphagia due to genetically confirmed Bardet-Biedl syndrome.
